会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • METHODS OF MODULATING SURFACTANT PRODUCTION
    • 调节表面活性剂生产的方法
    • WO2002095008A2
    • 2002-11-28
    • PCT/US2002/002728
    • 2002-01-30
    • BAYER CORPORATIONMASON, Robert, JamesNEBEN, StevenECKART, Michael, R.LONGPHRE, Malinda
    • MASON, Robert, JamesNEBEN, StevenECKART, Michael, R.LONGPHRE, Malinda
    • C12N
    • C07K14/4702A61K38/00
    • The present invention provides methods for modulating surfactant production using SREBP/ADD-1 polypeptides, and agonists or antagonists that are capable of modulating SREBP/ADD-1 activity. More particularly, the present invention encompasses the use of SREBP/ADD-1 polypeptides or agonist or antagonist polypeptides for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the SREBP/ADD-1 polypeptides or agonist or antagonist polypeptides and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
    • 本发明提供使用SREBP / ADD-1多肽以及能够调节SREBP / ADD-1活性的激动剂或拮抗剂来调节表面活性物质生成的方法。 更具体地,本发明包括SREBP / ADD-1多肽或激动剂或拮抗剂多肽用于治疗疾病或临床状况的用途,其中表面活性剂生产与疾病或临床病症的原因或治疗相关,例如肺 疾病包括成人/婴儿呼吸窘迫综合征,急性肺损伤,慢性阻塞性肺病(肺气肿和慢性支气管炎),哮喘,肺泡蛋白沉积和相关肺部疾病。 本发明还包括含有SREBP / ADD-1多肽或激动剂或拮抗剂多肽的药物组合物,以及这些药物组合物用于治疗上述疾病或临床病症的用途。
    • 10. 发明申请
    • METHODS OF MODULATING SURFACTANT PRODUCTION
    • 调节表面活性剂生产的方法
    • WO02074907A3
    • 2002-11-21
    • PCT/US0205134
    • 2002-01-30
    • BAYER AGMASON ROBERT JAMESNEBEN STEVENECKART MICHAEL RLONGPHRE MALINDA
    • MASON ROBERT JAMESNEBEN STEVENECKART MICHAEL RLONGPHRE MALINDA
    • A61K38/00A61K48/00C12N9/10A01N43/04C07H21/04C07K1/00C12N1/20C12N5/00C12N15/00C12P21/06C12Q1/00
    • C12N9/1029A61K38/00A61K48/00C12Y203/01085
    • The present invention provides methods of modulating surfactant production using FAS polypeptides, and agonists or antagonists that are capable of modulating FAS activity. More particularly, the present invention encompasses the use of FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, for the treatment of a disease or clinical condition where surfactant production is relevant to the causation or treatment of the disease or clinical condition, such as lung diseases, including adult/infant respiratory distress syndrome, acute lung injury, chronic obstructive pulmonary disease (emphysema and chronic bronchitis), asthma, alveolar proteinosis, small airway disease and maintaining airway patency, and related pulmonary conditions. The present invention also encompasses pharmaceutical compositions containing the FAS polypeptides, or agonist or antagonist polypeptides capable of modulating FAS activity, and the use of such pharmaceutical compositions for the treatment of the above-mentioned diseases or clinical conditions.
    • 本发明提供了使用FAS多肽和能够调节FAS活性的激动剂或拮抗剂调节表面活性剂产生的方法。 更特别地,本发明包括FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽用于治疗疾病或临床病症的用途,其中表面活性剂产生与疾病或临床病症的因果关系或治疗相关, 如肺部疾病,包括成人/婴儿呼吸窘迫综合征,急性肺损伤,慢性阻塞性肺病(肺气肿和慢性支气管炎),哮喘,肺泡蛋白沉积症,小气道疾病和保持呼吸道通畅以及相关的肺部疾病。 本发明还包括含有FAS多肽或能够调节FAS活性的激动剂或拮抗剂多肽的药物组合物,以及这些药物组合物用于治疗上述疾病或临床症状的用途。